All In Biotech

Drug Trial Radar · NCT07145151

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 2, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of UBT251 Injection in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

Jun 4, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose,6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.

Conditions

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions

  • UBT251Drug

    UBT251 administered subcutaneously (SC) once a week.

  • PlaceboDrug

    Placebo,SC,once a week for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver HistologyTime frame: Baseline, Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua ChangGung Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.